MONROE TOWNSHIP, N.J. & OXFORD, England, November 22, 2022--(BUSINESS WIRE)--Blue Earth Diagnostics, a Bracco institution and recognized person successful the improvement and commercialization of innovative PET radiopharmaceuticals, contiguous announced presentations connected Axumin® (fluciclovine F 18) astatine the upcoming Radiological Society of North America (RSNA) 108th Scientific Assembly and Annual Meeting, to beryllium held successful Chicago, Ill., from November 27 to December 1, 2022. Details of selected oral and poster presentations are listed below.
Two presentations from Emory University volition sermon further analyses from EMPIRE-1, the archetypal prospective, randomized controlled proceedings to show that 18F-fluciclovine PET/CT-guided radiation therapy improved event-free endurance rates successful men with biochemical recurrence of prostate cancer. Another presumption compares the diagnostic show of bony scintigraphy with 18F-fluciclovine successful detecting bony metastases successful men with prostate crab astatine assorted PSA levels. Details of selected oral and poster presentations by Blue Earth Diagnostics’ collaborators are listed below.
NOTE: Axumin® (fluciclovine F 18) injection is FDA-approved for PET imaging successful men with suspected prostate crab recurrence based connected elevated humor prostate-specific antigen (PSA) levels pursuing anterior treatment.
HIGHLIGHTED SCIENTIFIC PRESENTATIONS
Oral presentation | ||
Thursday, December 1, 2022 | ||
Title: | Failure-free Survival of Prostate Cancer Patients After Conventional Imaging Versus 18F-fluciclovine PET-guided Salvage Radiotherapy Stratified by Serum PSA Level: A Secondary Sub-group Analysis of a Randomized Control Trial | |
Presenter: | Ismaheel Lawal, MD, Division of Nuclear Medicine and Molecular Imaging, Department of Radiology and Imaging Sciences, Emory University, Atlanta, Ga. | |
Session Type: | Oral Scientific Session | |
Session Title: | Science Session with Keynote: Nuclear Medicine/Molecular Imaging (Prostate Cancer Imaging) | |
Presentation Time: | 1:30 – 2:30 PM CT | |
Location: | S402, McCormick Place | |
Presentation No.: | R-6-SNMMI 08-1 | |
Poster presentations | ||
Tuesday, November 29, 2022 | ||
Title: | Bone Scan versus F-18 Fluciclovine PET/CT astatine Different PSA Levels: A Single Center Comparison Study | |
Presenter: | Hatice Savas, MD, Associate Professor, Feinburg School of Medicine, Northwestern University, Chicago, Ill. | |
Session Type: | Scientific Poster Session | |
Session Title: | Nuclear Medicine/Molecular Imaging Tuesday Poster Discussion | |
Presentation Time: | 9:00 – 9:30 AM CT | |
Location: | Learning Center NMMI-DPS, McCormick Place | |
Session No.: | T2-SPNMMI-1 | |
Title: | Impact of 18F-fluciclovine PET/CT connected Failure-free Survival successful Biochemical Recurrence of Prostate Cancer Following Salvage Radiation Therapy | |
Presenter: | Charles Marcus, MBBS, Assistant Professor, Department of Imaging and Radiology Sciences, Emory University School of Medicine, Atlanta, Ga. | |
Session Type: | Scientific Poster Session | |
Session Title: | Nuclear Medicine/Molecular Imaging Tuesday Poster Discussion - A | |
Presentation Time: | 12:15 – 12:45 PM CT | |
Location: | Learning Center NMMI-DPS, McCormick Place | |
Session No.: | T5A-SPNMMI-2 | |
Axumin® (fluciclovine F 18) presentations
Blue Earth Diagnostics invites participants astatine RSNA 2022 to be the presentations above. For afloat league details and technological presumption listings, delight spot the RSNA 2022 online programme here.
Indication and Important Safety Information About Axumin
INDICATION
Axumin® (fluciclovine F 18) injection is indicated for positron emanation tomography (PET) imaging successful men with suspected prostate crab recurrence based connected elevated humor prostate circumstantial antigen (PSA) levels pursuing anterior treatment.
IMPORTANT SAFETY INFORMATION
Image mentation errors tin hap with Axumin PET imaging. A antagonistic representation does not regularisation retired recurrent prostate crab and a affirmative representation does not corroborate its presence. The show of Axumin seems to beryllium affected by PSA levels. Axumin uptake whitethorn hap with different cancers and benign prostatic hypertrophy successful superior prostate cancer. Clinical correlation, which whitethorn see histopathological evaluation, is recommended.
Hypersensitivity reactions, including anaphylaxis, whitethorn hap successful patients who person Axumin. Emergency resuscitation instrumentality and unit should beryllium instantly available.
Axumin usage contributes to a patient’s wide semipermanent cumulative radiation exposure, which is associated with an accrued hazard of cancer. Safe handling practices should beryllium utilized to minimize radiation vulnerability to the diligent and wellness attraction providers.
Adverse reactions were reported successful ≤ 1% of subjects during objective studies with Axumin. The astir communal adverse reactions were injection tract pain, injection tract erythema and dysgeusia.
To study suspected adverse reactions to Axumin, telephone 1-855-AXUMIN1 (1-855-298-6461) oregon interaction FDA astatine 1-800-FDA-1088 oregon www.fda.gov/medwatch.
Full Axumin prescribing accusation is disposable astatine https://www.axumin.com/prescribing-information.pdf.
About Blue Earth Diagnostics
Blue Earth Diagnostics, an indirect subsidiary of Bracco Imaging S.p.A., is simply a increasing planetary molecular imaging institution focused connected delivering innovative, well-differentiated diagnostic solutions that pass diligent care. Formed successful 2014, the Company’s occurrence is driven by its absorption expertise and supported by a demonstrated way grounds of accelerated improvement and commercialization of positron emanation tomography (PET) radiopharmaceuticals. Blue Earth Diagnostics’ expanding oncology portfolio encompasses a assortment of illness states, including prostate crab and neuro-oncology. Blue Earth Diagnostics is committed to the timely improvement and commercialization of precision radiopharmaceuticals for imaginable usage successful imaging and therapy. For much information, delight visit: www.blueearthdiagnostics.com.
About Bracco Imaging
Bracco Imaging S.p.A., portion of the Bracco Group, is simply a world-leading diagnostic imaging provider. Headquartered successful Milan, Italy, Bracco Imaging develops, manufactures and markets diagnostic imaging agents and solutions. It offers a merchandise and solution portfolio for each cardinal diagnostic imaging modalities: X-ray imaging (including Computed Tomography-CT, Interventional Radiology, and Cardiac Catheterization), Magnetic Resonance Imaging (MRI), Contrast Enhanced Ultrasound (CEUS), and Nuclear Medicine done radioactive tracers and caller PET imaging agents to pass objective absorption and usher attraction for crab patients successful areas of unmet aesculapian need. Our continually evolving portfolio is completed by a scope of aesculapian devices, precocious medication systems and dose-management software. In 2019 Bracco Imaging besides enriched its merchandise portfolio by expanding the scope of oncology atomic imaging solutions successful the urology conception and different specialties with the acquisition of Blue Earth Diagnostics. Visit: www.braccoimaging.com.
View root mentation connected businesswire.com: https://www.businesswire.com/news/home/20221122005034/en/
Contacts
English (US)